ClinicalTrials.gg

Program

guselkumab

Also written as “Guselkumab”, “Guselkumab Dose 1” and “Guselkumab Dose 2”.

Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.

Furthest: phase 4, since Jun 3, 202160 company-led studies, 19 open or runningNext primary completion: Nov 20, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson5818 open or runningphase 4since Jun 3, 2021Sep 2, 2011Feb 10, 2027phase 3 · NCT06260163
Eli Lilly10 open or runningphase 4since Jun 20, 2018Jun 20, 2018none ahead
Surmount Services11 open or runningphase 1since Aug 20, 2026Aug 20, 2026Nov 20, 2026phase 1 · NCT07788807

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Sep 2, 2011.

  1. Mar 1, 2022Phase 3 study in Plaque PsoriasisJohnson & Johnson · NCT05272150 · 211 enrolled · United States, Canada
  2. Apr 21, 2022Phase 3 study in Fistulizing Crohns DiseaseJohnson & Johnson · NCT05347095 · 288 enrolled · United States, Australia, Belgium and more
  3. Aug 19, 2022Phase 3 study in Colitis, UlcerativeJohnson & Johnson · NCT05528510 · 418 enrolled · United States, Argentina, Australia and more
  4. Mar 13, 2023Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT05784129 · 4 enrolled · United States, Poland
  5. Jun 20, 2023Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT05923073 · 120 planned · United States, Australia, Austria and more
  6. Sep 9, 2023Phase 3 study in Moderate Plaque PsoriasisJohnson & Johnson · NCT06039189 · 338 enrolled · United States, Canada
  7. Feb 7, 2024Phase 3 study in Colitis, UlcerativeJohnson & Johnson · NCT06260163 · 112 enrolled · United States, Australia, Belgium and more
  8. May 7, 2024Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT06408935 · 120 enrolled · United States, Australia, Belgium and more
  9. Oct 28, 2024Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT06663332 · 196 planned · United States, Argentina, Australia and more
  10. Aug 21, 2025Phase 4 study in Arthritis, PsoriaticJohnson & Johnson · NCT07141004 · 100 planned · India
  11. Dec 16, 2025Phase 4 study in Crohn DiseaseJohnson & Johnson · NCT07310095 · 78 planned · China
  12. Mar 23, 2026Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT07499232 · 530 planned · United States, Austria, Belgium and more
  13. Jun 12, 2026Phase 4 study in PsoriasisJohnson & Johnson · NCT07654751 · 10 planned · United States
  14. Aug 20, 2026Surmount Services's first study: phase 1 study in Healthy SubjectsNew to Surmount ServicesSurmount Services · NCT07788807 · 18 planned · Australia

Ahead

  1. Nov 20, 2026Primary completion: phase 1 study in Healthy SubjectsSurmount Services · NCT07788807
  2. Feb 10, 2027Primary completion: phase 3 study in Colitis, UlcerativeJohnson & Johnson · NCT06260163
  3. Mar 25, 2027Primary completion: phase 3 study in Fistulizing Crohns DiseaseJohnson & Johnson · NCT05347095
  4. Apr 1, 2027Primary completion: phase 4 study in Arthritis, PsoriaticJohnson & Johnson · NCT04929210

TargetBeta

IL12B →IL23A →read by rule
“Interleukin-23 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
risankizumabruleAbbViephase 468
mirikizumabruleEli Lillyphase 436

Studies

All 60 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07788807Healthy Subjects · Australia1RecruitingSurmount ServicesNov 20, 202618
NCT07654751Psoriasis · United States4RecruitingJohnson & JohnsonAug 31, 202710
NCT07499232Crohn Disease · United States, Austria, Belgium and more3RecruitingJohnson & JohnsonNov 15, 2028530
NCT07310095Crohn Disease · China4RecruitingJohnson & JohnsonSep 15, 202778
NCT07141004Arthritis, Psoriatic · India4RecruitingJohnson & JohnsonJun 5, 2027100
NCT06663332Crohn Disease · United States, Argentina, Australia and more3RecruitingJohnson & JohnsonDec 12, 2031196
NCT06408935Crohn Disease · United States, Australia, Belgium and more3Active, not recruitingJohnson & JohnsonJun 8, 2027120
NCT06260163Colitis, Ulcerative · United States, Australia, Belgium and more3Active, not recruitingJohnson & JohnsonFeb 10, 2027112
NCT06039189Moderate Plaque Psoriasis · United States, Canada3CompletedJohnson & JohnsonApr 14, 2025338
NCT05923073Crohn Disease · United States, Australia, Austria and more3RecruitingJohnson & JohnsonOct 27, 2027120
NCT05784129Crohn Disease · United States, Poland3TerminatedJohnson & JohnsonSep 29, 20234
NCT05528510Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonApr 2, 2024418
NCT05347095Fistulizing Crohns Disease · United States, Australia, Belgium and more3Active, not recruitingJohnson & JohnsonMar 25, 2027288
NCT05272150Plaque Psoriasis · United States, Canada3CompletedJohnson & JohnsonMay 30, 2025211
NCT05242484Colitis, Ulcerative · United States, Argentina, Australia and more2Active, not recruitingJohnson & JohnsonMay 15, 2025577
NCT05242471Crohn Disease · United States, Australia, Austria and more2Active, not recruitingJohnson & JohnsonMay 23, 2025703
NCT05197049Crohn Disease · United States, Australia, Belgium and more3Active, not recruitingJohnson & JohnsonJul 4, 2023350
NCT05125679Psoriasis · Germany, Greece, Italy4TerminatedJohnson & JohnsonJul 28, 202315
NCT05083078Arthritis, Psoriatic · Austria1TerminatedJohnson & JohnsonJul 1, 202211
NCT05083182Arthritis, Juvenile · United States, Argentina, Denmark and more3CompletedJohnson & JohnsonJan 12, 202648
NCT04936308Arthritis, Psoriatic · United States, Argentina, Australia and more3CompletedJohnson & JohnsonOct 28, 2024453
NCT04929210Arthritis, Psoriatic · United States, Argentina, Australia and more4Active, not recruitingJohnson & JohnsonApr 1, 2027411
NCT04914429Psoriasis · China4CompletedJohnson & JohnsonSep 26, 2023327
NCT04882098Arthritis, Psoriatic · United States, Australia, Bosnia and Herzegovina and more3Active, not recruitingJohnson & JohnsonDec 30, 20241,054
NCT04704843Celiac Disease · United States1WithdrawnJohnson & JohnsonSep 13, 20210
NCT04683029Scleroderma, Systemic · Japan2CompletedJohnson & JohnsonMay 17, 202356
NCT04633447Giant Cell Arteritis · United States, Belgium, Canada and more2TerminatedJohnson & JohnsonMay 22, 202453
NCT04617691Healthy · Germany1CompletedJohnson & JohnsonJul 20, 2021140
NCT04397263Crohn Disease · Japan3CompletedJohnson & JohnsonFeb 29, 202438
NCT04376827Lupus Nephritis · United States, Argentina, Mexico and more2TerminatedJohnson & JohnsonFeb 1, 202333
NCT04147338Healthy · United States, Germany1CompletedJohnson & JohnsonSep 13, 2021440
NCT04033445Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonSep 19, 20231,064
NCT04030533Healthy · China1CompletedJohnson & JohnsonDec 31, 202060
NCT03998683Psoriasis · France, Germany, Italy and more3CompletedJohnson & JohnsonMar 2, 2021117
NCT03818035Psoriasis · France, Germany3CompletedJohnson & JohnsonMar 7, 2022880
NCT03796858Arthritis, Psoriatic · Belgium, Bulgaria, France and more3CompletedJohnson & JohnsonNov 11, 2020285
NCT03662542Colitis, Ulcerative · United States, Argentina, Australia and more2CompletedJohnson & JohnsonDec 1, 2020214
NCT03649971Adenomatous Polyposis Coli · United States, France, Germany and more1CompletedJohnson & JohnsonSep 13, 202177
NCT03628924Hidradenitis Suppurativa · United States, Canada, Denmark and more2CompletedJohnson & JohnsonMay 22, 2020184
NCT03573323Plaque Psoriasis · United States, Canada, Puerto Rico4CompletedEli LillyJul 15, 20191,027
NCT03536325Healthy · Japan1CompletedJohnson & JohnsonOct 25, 201824
NCT03466411Crohn Disease · United States, Australia, Austria and more3Active, not recruitingJohnson & JohnsonOct 20, 20231,409
NCT03451851Psoriasis · United States, Australia, Belgium and more3Active, not recruitingJohnson & JohnsonJul 19, 2023120
NCT03162796Arthritis, Psoriatic · United States, Australia, Canada and more3CompletedJohnson & JohnsonMar 14, 2019383
NCT03158285Arthritis, Psoriatic · United States, Bulgaria, Czechia and more3CompletedJohnson & JohnsonFeb 25, 2019741
NCT03090100Psoriasis · United States, Australia, Canada and more3CompletedJohnson & JohnsonAug 2, 20181,048
NCT02951533Psoriasis · Germany3CompletedJohnson & JohnsonSep 13, 2017119
NCT02905331Psoriasis · United States, Canada, Poland3CompletedJohnson & JohnsonFeb 6, 201878
NCT02641730Psoriasis · Japan3CompletedJohnson & JohnsonMar 28, 2017159
NCT02570373Healthy · United States1CompletedJohnson & JohnsonJan 12, 20168
NCT02397382Psoriasis · United States1CompletedJohnson & JohnsonAug 31, 201616
NCT02343744Psoriasis · Japan3CompletedJohnson & JohnsonDec 4, 201521
NCT02325219Psoriasis · Japan3CompletedJohnson & JohnsonMar 2, 2016192
NCT02319759Arthritis, Psoriatic · United States, Canada, Germany and more2CompletedJohnson & JohnsonMay 31, 2016149
NCT02203032Psoriasis · United States, Australia, Canada and more3CompletedJohnson & JohnsonDec 25, 2015872
NCT01866007Healthy · United States1CompletedJohnson & JohnsonSep 20, 2013141
NCT01845987Psoriasis · Japan2CompletedJohnson & JohnsonSep 201449
NCT01645280Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more2CompletedJohnson & JohnsonDec 2013274
NCT01483599Psoriasis · United States, Belgium, Canada and more2CompletedJohnson & JohnsonNov 27, 2012293
NCT01484587Psoriasis · Japan1CompletedJohnson & JohnsonApr 11, 201324

How it is read

Names in the registry

  • “Guselkumab”, 43 entries
  • “Guselkumab Dose 1”, 7 entries
  • “Guselkumab Dose 2”, 7 entries
  • “Guselkumab Dose 3”, 4 entries
  • “Guselkumab 100 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.